Aurora Cannabis Unveils Major Investments and New Name for B.C. Facility

On April 30, 2025, Aurora Cannabis Inc., a frontrunner in the medical cannabis landscape, made an announcement that reflects its commitment to excellence and innovation. The company has finalized a significant investment of $3 million in renovations and enhancements at its manufacturing site located in Pemberton, British Columbia, previously known as the Whistler Medical Marijuana Company. The newly rebranded facility is now called Aurora Alpine, a name which symbolizes both the site's breathtaking views of Mount Currie and the pinnacle of cannabis quality and production efficiency that Aurora is striving to achieve.

Investing in Operational Excellence

Over the last three years, Aurora's dedication to improving yield and potency at the facility has borne fruit, doubling its yield while achieving an impressive potency rate of 33.7%. Alex Miller, the Executive Vice President of Operations and Supply Chain, articulates that the Aurora Alpine name encapsulates their commitment to superior growing practices driven by genetic technology and bolstered by a dedicated team. This investment is a testament to Aurora's long-standing mission of prioritizing operational excellence.

These upgrades have been meticulously designed, combining Aurora's proprietary genetics with advanced engineering practices to establish optimal cultivation conditions. As a result, the site can produce higher quality products at an expanded capacity. This positioning not only enhances Aurora's roots in the Canadian cannabis marketplace but also allows the firm to broaden its global reach by exporting premium medical cannabis internationally.

A Legacy of Quality

The facility, originally licensed in 2019, has a distinguished legacy of delivering award-winning cannabis. With GACP certification, Aurora Alpine is well-equipped to meet the demands of international markets, showcasing premium products cultivated under stringent quality control standards.

The careful integration of cutting-edge cultivation technologies and proprietary genetics not only amplifies production efficiency but also sets new benchmarks within the industry for operational efficacy and cultivation precision. Aurora’s continuous pursuit of improvement is what fundamentally positions it as a global leader, constantly reshaping the future landscape of the cannabis industry.

Expanding its Global Footprint

As Aurora Cannabis expands globally, it bridges the gap between the medical and consumer markets across multiple continents, including Canada, Europe, Australia, and New Zealand. Their diverse brand roster features an array of adult-use and medical cannabis products, such as Drift, San Rafael '71, and MedReleaf. The company maintains its headquarters in Edmonton, Alberta, embodying its pioneering spirit in the cannabis sector.

Aurora's commitment to high-quality products is evident in their ongoing investment strategy and willingness to embrace technological advancements. This dynamic approach consistently pushes their brand to the forefront of both medical and recreational cannabis markets. Investors and consumers alike can expect that such industry-leading efforts combined with a focus on scientific innovation will continue to yield tangible benefits.

For those interested in learning more about Aurora Cannabis Inc. and the transformative developments taking place at Aurora Alpine, further information is available at www.auroramj.com or through their social media channels on X and LinkedIn. The future looks promising for Aurora as they strive to redefine excellence in the cannabis industry.

In essence, Aurora Cannabis’s bold step forward with its investments and rebranding initiative at the Pemberton facility reflects a broader ambition—capturing a significant share of the global cannabis market while ensuring product integrity and innovation remain at the forefront of their operations.